Pharmacogenetics Testing in Psychiatry/Depression Market to Observe Utmost CAGR of 9.5% by 2029
Global Pharmacogenetics Testing in Psychiatry/Depression Market report highlights all-inclusive professional study of the HELATH industry which focuses on primary and secondary drivers, market share, competitor analysis, leading segments and geographical analysis. This global market research report is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis.
Pharmacogenetic testing helps medical professionals by providing information on how a person metabolizes a medication. This information can help doctors and others avoid prescribing antidepressants that could produce undesirable outcomes. Pharmacogenomics has shown promise for predicting antidepressant response and tolerability in major depressive disorder (MDD). Pharmacogenomics can improve clinical outcomes by guiding antidepressant selection and dosing. The growing biotechnology sector, and increasing health expenditure, have accelerated the demand for pharmacogenetic testing in psychiatry/depression.
Download PDF Sample Report (Including Graphs, Charts, and List of Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pharmacogenetic-testing-in-psychiatry-depression-market&Shri
The growing prevalence of cancer disease, novel technology in the treatment of depression and/or other psychiatric conditions are increasing the adoption of pharmacogenetics testing in psychiatry/depression devices and procedures, and the rising preference for non-surgical procedures are the major drivers which propelled the demand for the market in the forecast period. However, the high cost associated with the tests, stringent regulation, and lack of awareness may expect to hamper the pharmacogenetics testing in psychiatry/depression market growth in the forecast period.
Data Bridge Market Research analyzes that the global pharmacogenetics testing in psychiatry/depression market is expected to reach the value of USD 2,133.49 million by 2029, at a CAGR of 9.5% during the forecast period. Anxiety accounts for the largest type segment in the market due to the increasing depression rate among the global population. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.
Market Overview:
Pharmacogenomic testing has recently become scalable and available to guide major depressive disorder (MDD). Clinicians increasingly recognize Pharmacogenomic (PGx) testing as an essential tool to guide medication decisions for psychiatric illnesses. Extensive implementation of PGx testing is driving the market in the forecast period.
The terms personalized medicine, stratified medicine, and precision medicine are close relatives of pharmacogenetics, but these are broader terms that also cover additional non-genetic factors. Nevertheless, pharmacogenetics is an important component of these areas. Pharmacogenetics is primarily concerned with human germline DNA variation, but there have also been important recent advances in understanding mood disorders, and mental illnesses.
Pharmacogenetics testing studies the interaction between drug and gene response of a person and searches for the gene variation which is responsible for influencing the drug effect. The test is gaining high demand as many researchers and scientists identified the unique interaction between drugs and individual genes and provides valuable insights which subsequently be used to develop customized or personalized medication.
Recent Developments
- In April 2022, Blue Care Network (BCN) launched a precision medicine program, Blue Cross Personalized Medicine, which leverages pharmacogenomics, or genetic testing, to personalize and tailor medication treatments more effectively for select members based on a review of their prescribed medications for various diagnosis including behavioral health, cardiology, cardiovascular and oncology. OneOme LLC has helped BCN achieve its precision medicine program goals and reduce the total cost of care and improve patient health outcomes by reducing adverse drug reactions. This has helped the company to enhance its product portfolio
Some of the major players operating in the global pharmacogenetics testing in psychiatry/depression market are
- Genelex (Part of Invitae corporation)
- Genewiz (Part of Azenta Life Sciences)
- MD Labs
- BiogeneiQ, Inc.
- ONEOME, LLC
- Myriad Genetics, Inc.
- GenXys
- Castle Biosciences, Inc.
- PacBio
- QIAGEN
- Thermo Fisher Scientific Inc.
- AB-Biotics.S.A.
- Coriell Life Sciences
- Eurofins Scientific
- Illumina, Inc.
- Dynamic DNA Laboratories
- STADAPHARM GmbH
- Color Health, Inc.
- Cnsdose
- Genomind, Inc.
- Healthspek
- myDNA Life Australia Pty Ltd.
- HudsonAlpha
- Sonic Healthcare Limited
To Gain More Insights into the Market Analysis, Browse Summary of the Research Report@ https://www.databridgemarketresearch.com/reports/global-pharmacogenetic-testing-in-psychiatry-depression-market?Shri
Global Pharmacogenetics Testing in Psychiatry/Depression Market Scope
Global pharmacogenetics testing in psychiatry/depression market is segmented into type, test type, gene type, patient type, product, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- Global Pharmacogenetics Testing In Psychiatry/Depression Market, By Type
- Anxiety
- Mood Disorders
- Depression
- Bipolar Disorders
- Psychotic Disorders
- Eating Disorders
On the basis of type, global pharmacogenetics testing in psychiatry/depression market is segmented into anxiety, mood disorders, depression, bipolar disorders, psychotic disorders, and eating disorders.
- Global Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type
- Whole Genome Sequencing
- Chromosomal Array-Based Tests
On the basis of test type, global pharmacogenetics testing in psychiatry/depression market is segmented into whole genome sequencing, and chromosomal array-based tests.
- Global Pharmacogenetics Testing In Psychiatry/Depression Market, By Gene Type
- CYP2C19
- CYP2C9 AND VKORC1
- CYP2D6
- HLA-B
- HTR2A/C
- HLA-A
- CYP3A4
- SLC6A4
- MTHFR
- COMT
- OTHERS
On the basis of gene type, global pharmacogenetics testing in psychiatry/depression market is segmented into CYP2C19, CYP2C9, VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and others.
- Global Pharmacogenetics Testing In Psychiatry/Depression Market, By Patient Type
- Child
- Adult
- Geriatric
On the basis of patient type, the global pharmacogenetics testing in psychiatry/depression market is segmented into children, adults, and geriatrics.
- Global Pharmacogenetics Testing In Psychiatry/Depression Market, By Product
- Instruments
- Consumable
- Software & Services
On the basis of product type, global pharmacogenetics testing in psychiatry/depression market is segmented into instruments, consumables, and software & services.
- Global Pharmacogenetics Testing In Psychiatry/Depression Market, By End User
- Hospitals & Clinics
- Dignostics Laboratories
- Academic And Research Institutes
- Others
On the basis of end user, global pharmacogenetics testing in psychiatry/depression market is segmented into hospitals and clinics, diagnostics laboratories, academic and research institutes, and others.
- Global Pharmacogenetics Testing in Psychiatry/Depression Market, By Distribution Channel
- Direct Tender
- Third-Party Distribution
- Hospital Pharmacy
- Others
Rise in demand for personalized and precision medicine is expected to drive the market’s growth rate
The pharmacogenetics test assists medical professionals in selecting the best medicine for the patient because it searches for gene variants that may be responsible for influencing the drug’s effect.
Medicine is becoming more personalized, and patients are increasingly interested in better outcomes and fewer side effects with personalized medications. Personalized medicine has the potential to tailor therapy with a high margin of safety and the best response. Advancements largely drive this trend in genome sequencing. The shift toward personal healthcare necessitates changes in pharmaceutical manufacturing. Manufacturers are moving from creating small molecules to the combination of small molecule and gene therapies. Sponsors focus on replacing inefficient large-scale batch production with investments in new technology and producing personalized drugs.
Browse the complete table of contents at – https://www.databridgemarketresearch.com/toc/?dbmr=global-pharmacogenetic-testing-in-psychiatry-depression-market&Shri
Top DBMR Healthcare Reports:
https://www.databridgemarketresearch.com/reports/global-optic-nerve-atrophy-treatment-market
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com
